NASDAQ:PTIX Atrinsic Q2 2026 Earnings Report $0.26 0.00 (0.00%) As of 07/16/2026 ProfileEarnings HistoryForecast Atrinsic EPS ResultsActual EPS-$0.47Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AAtrinsic Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAtrinsic Announcement DetailsQuarterQ2 2026Date11/26/2025TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AUpcoming EarningsAtrinsic's next earnings date is estimated for Tuesday, August 18, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Atrinsic Earnings HeadlinesAtrinsic (NASDAQ:PTIX) Trading 15.8% Higher - Still a Buy?July 10, 2026 | americanbankingnews.comProtagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug CandidatesJuly 30, 2025 | globenewswire.comBuy this stock tomorrowMarc Chaikin, founder of Chaikin Analytics, is flagging a little-known company that just secured a partnership with Nvidia - one he believes positions it ahead of Tesla in the autonomous vehicle race. With a market-moving announcement expected on July 31st, Chaikin is urging investors to swap overpriced AI stocks for this under-the-radar name before markets open. He's also releasing a free Hotlist and Hitlist of buy and sell ideas for the second half of 2026. | Chaikin Analytics (Ad)Protagenic Therapeutics, Inc. (PTIX) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comProtagenic & Phytanix Merge in All-Stock Move, Sparking Retail FrenzyMay 29, 2025 | msn.comProtagenic Therapeutics swaps warrants for sharesMay 21, 2025 | uk.investing.comSee More Atrinsic Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Atrinsic? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Atrinsic and other key companies, straight to your email. Email Address About AtrinsicProtagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.View Atrinsic ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles TSMC Just Gave AI Chip Bulls Another Reason to Stay ConfidentAehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue GrowthGE Aerospace Faces a Prove-It Moment in Q2 EarningsWhy Abbott Laboratories Stock Is Suddenly Winning Back Wall StreetJ.B. Hunt Stock Could Reach $340 as Trucking Capacity ShrinksPalantir's Wild Ride: Inside the Stock Wall Street Can't Agree OnRevving Up Returns: Big Banks Race Through the Rate Plateau Upcoming Earnings General Motors (7/21/2026)Northrop Grumman (7/21/2026)America Movil (7/21/2026)Alphabet (7/21/2026)Chubb (7/21/2026)Capital One Financial (7/21/2026)Interactive Brokers Group (7/21/2026)Charles Schwab (7/21/2026)Danaher (7/21/2026)Novartis (7/21/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
